Sangeeta Bhaskar

Dr. Sangeeta Bhaskar

National Institute of Immunology, New Delhi, Delhi, International

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSurendra K. Sharma
Surendra K. Sharma
KKKiran Katoch
Kiran Katoch
RSRohit Sarin
Rohit Sarin
RBRaman Balambal
Raman Balambal
NJNirmal Kumar Jain
Nirmal Kumar Jain
RRRajni Rani
Rajni Rani
Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB). We have evaluated the immunotherapeutic potential of Mycobacterium indicus pranii (MIP) as an adjunct to Anti-Tubercular Treatment (ATT) in Cat II pulmonary TB (PTB) patients in a prospective, randomized, double blind, placebo controlled, multicentric clinical trial. 890 sputum smear positive Cat II PTB patients were randomized to receive either six intra-dermal injections (2 + 4) of heat-killed MIP at a dose of 5 × 108 bacilli or placebo once in 2 weeks for 2 months. Sputum smear and culture examinations were performed at different time points. MIP was safe with no adverse effects. While sputum smear conversion did not show any statistically significant difference, significantly higher number of patients (67.1%) in the MIP group achieved sputum culture conversion at fourth week compared to the placebo (57%) group (p = 0.0002), suggesting a role of MIP in clearance of the bacilli. Since live bacteria are the major contributors for sustained incidence of TB, the potential of MIP in clearance of the bacilli has far reaching implications in controlling the spread of the disease.

26 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAnkan Gupta
Ankan Gupta
FAFarhan Jalees Ahmad
Farhan Jalees Ahmad
FAFaiz Ahmad
Faiz Ahmad
UGUmesh D. Gupta
Umesh D. Gupta
MNMohan Natarajan
Mohan Natarajan
SBSangeeta Bhaskar
Sangeeta Bhaskar
The 9-month-long chemotherapy of tuberculosis often results in poor compliance and emergence of drug-resistant strains. So, improved therapeutic strategy is urgently needed. Immunotherapy could be beneficial for the effective management of the disease. Previously we showed the protective efficacy of Mycobacterium indicus pranii (MIP) when given as prophylactic vaccine in animal models of tuberculosis. We sought to investigate whether MIP can be used as an adjunct to the chemotherapy in guinea pig models of tuberculosis. Efficacy of MIP was evaluated when given subcutaneously or by aerosol. MIP-therapy as an adjunct to the chemotherapy was found to be effective in accelerating bacterial killing and improving organ pathology. MIP-immunotherapy resulted in higher numbers of activated antigen-presenting cells and lymphocytes in the infected lungs and also modulated the granulomatous response. Early increase in protective Th1 immune response was observed in the immunotherapy group. Following subsequent doses of MIP, decrease in the inflammatory response and increase in the immunosuppressive response was observed, which resulted in the improvement of lung pathology. MIP immunotherapy is a valuable adjunct to chemotherapy for tuberculosis. Aerosol route of immunotherapy can play a crucial role for inducing immediate local immune response in the lung.

1 March 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ARAniruddha Roy
Aniruddha Roy
MSManu Smriti Singh
Manu Smriti Singh
PUPramod Upadhyay
Pramod Upadhyay
SBSangeeta Bhaskar
Sangeeta Bhaskar

1 January 2009 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
AGAnkan Gupta
Ankan Gupta
NGNishamol Geetha
Nishamol Geetha
JMJiju Mani
Jiju Mani
PUPramod Upadhyay
Pramod Upadhyay
VKV. M. Katoch
V. M. Katoch
SBSangeeta Bhaskar
Sangeeta Bhaskar
As the disease caused by Mycobacterium tuberculosis continues to be a burden, there is a concerted effort to find new vaccines to combat this problem. One of the important vaccine strategies is whole bacterial vaccines. This approach relies on multiple antigens and built-in adjuvanticity. Other mycobacterial strains which share cross-reactive antigens with M. tuberculosis have been considered as alternatives to M. bovis for vaccine use. One such strain, “ Mycobacterium w ”, had been evaluated for its immunomodulatory properties in leprosy. A vaccine against leprosy based on killed M. w is approved for human use, where it has resulted in clinical improvement, accelerated bacterial clearance, and increased immune responses to Mycobacterium leprae antigens. M. w shares antigens not only with M. leprae but also with M. tuberculosis , and initial studies have shown that vaccination with killed M. w induces protection against tuberculosis in Mycobacterium bovis BCG responder, as well as BCG nonresponder, strains of mice. Hence, we further studied the protective potential of M. w and the underlying immune responses in the mouse model of tuberculosis. We analyzed the protective efficacy of M. w immunization in both live and killed forms through the parenteral route and by aerosol immunization, compared with that of BCG. Our findings provide evidence that M. w has potential protective efficacy against M. tuberculosis. M. w activates macrophage activity, as well as lymphocytes. M. w immunization by both the parenteral route and aerosol adminstration gives higher protection than BCG given by the parenteral route in the mouse model of tuberculosis.

7 September 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ARAniruddha Roy
Aniruddha Roy
MSManu Smriti Singh
Manu Smriti Singh
PUPramod Upadhyay
Pramod Upadhyay
SBSangeeta Bhaskar
Sangeeta Bhaskar

30 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FAFaiz Ahmad
Faiz Ahmad
JMJiju Mani
Jiju Mani
PKPawan Kumar
Pawan Kumar
SHSeenu Haridas
Seenu Haridas
PUPramod Upadhyay
Pramod Upadhyay
SBSangeeta Bhaskar
Sangeeta Bhaskar
Role of immune system in protecting the host from cancer is well established. Growing cancer however subverts immune response towards Th2 type and escape from antitumor mechanism of the host. Activation of both innate and Th1 type response is crucial for host antitumor activity. In our previous study it was found, that Mycobacterium indicus pranii (MIP) also known as M. w induces Th1 type response and activates macrophages in animal model of tuberculosis. Hence, we studied the immunotherapeutic potential of MIP in mouse tumor model and the underlying mechanisms for its antitumor activity. Tumors were implanted by injecting B16F10 melanoma cells subcutaneously into C57BL/6 mice. Using the optimized dose and treatment regimes, anti-tumor efficacy of heat killed MIP was evaluated. In MIP treated group, tumor appeared in only 50–60% of mice, tumor growth was delayed and tumor volume was less as compared to control. MIP mediated immune activation was analysed in the tumor microenvironment, tumor draining lymph node and spleen. Induction of Th1 response and higher infiltration of immune cells in the tumor microenvironment was observed in MIP treated mice. A large fraction of these immune cells were in activated state as confirmed by phenotypic and functional analysis. Interestingly, percentage of Treg cells in the tumor milieu of treated mice was less. We also evaluated efficacy of MIP along with chemotherapy and found a better response as compared to chemotherapy alone. MIP therapy is effective in protecting mice from tumor. It activates the immune cells, increases their infiltration in tumor, and abrogates tumor mediated immune suppression.